Understanding genetic factors in hereditary paraganglioma and pheochromocytoma syndrome
Official title: Inherited genetic variation and penetrance of Hereditary Paraganglioma-Pheochromocytoma Syndrome
Funded at University of Colorado Denver · NIH-10834053 · Data updated 2026-11-12
This study is looking at how certain genes might affect the chances of developing adrenal tumors called paragangliomas and pheochromocytomas, so if you or someone you know is at risk, this research could help improve testing and treatment options for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 4, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $337,990 |
| NIH project number | 5R01CA246586-05 |
| Project ID | NIH-10834053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of paraganglioma or pheochromocytoma, particularly those who may carry genetic variants in the SDH genes.
✕Less likely to help
Patients without a hereditary predisposition to paraganglioma or pheochromocytoma, or those with sporadic cases not linked to genetic factors, may not benefit from this research.
What this research studies
This research investigates the genetic variations that contribute to hereditary paraganglioma and pheochromocytoma syndrome, which are types of tumors that can affect the adrenal glands. The study aims to identify specific genetic markers that can predict the likelihood of developing these tumors and their potential for metastasis. By analyzing the Succinate Dehydrogenase Subunit (SDH) genes and their role in tumor development, the research seeks to improve screening and surveillance recommendations for at-risk individuals. Patients may be involved in genetic testing to help clarify their risk and guide future treatment options.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of cancer risk and more personalized treatment plans for patients with hereditary paraganglioma and pheochromocytoma syndrome.
How similar studies have gone: Previous research has shown promise in identifying genetic markers for other hereditary cancers, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Fishbein, Lauren Michelle — University of Colorado Denver
- Study coordinator: Fishbein, Lauren Michelle
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic background affects rare tumors and their treatment responses
This study is looking at how your genetic background might affect the way rare tumors called pheochromocytomas and paragangliomas behave and respond to treatment, especially for patients from underrepresented racial and ethnic groups, to help find better ways to detect and treat these tumors.
-
Identifying weaknesses in a type of cancer linked to genetic mutations.
This study is looking at a type of inherited cancer called familial paraganglioma to find out how certain genetic weaknesses in cancer cells can help us develop new treatments that specifically target those weaknesses.
-
NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma
This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
-
Registry for Rare Diseases
This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.